Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10149846 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10149834 | 0.89 | ALDH1A1 (0.55) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3321650 | 0.89 | ALDH1A1 (0.55) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10149821 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10149819 | 0.87 | MAPT (0.56) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10149844 | 0.87 | ALDH1A1 (0.70) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10149843 | 0.85 | TP53 (0.56) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10149853 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10149852 | 0.84 | ALDH1A1 (0.73) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10149827 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171419-A1 | ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP (US) | 2014-06-19 | — | — | US | disclosed |
| US-8193177-B2 | Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases | ANGION BIOMEDICA CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2011019400-A2 | ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | ANGION BIOMEDICA CORP. | 2010-10-07 | — | — | US | disclosed |
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7648978-B2 | Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone | ANGION BIOMEDICA CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| WO-2009064422-A2 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | ANGION BIOMEDICA CORP. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137285-A1 | SMALL MOLECULE MODULATORS OF CYTOKINE ACTIVITY | HGF, IL2, IL2RA | ALDH1A1 978/4885MAPT 3078/4885KMT2A 3896/4885 |
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | HGF, HDGF, HGFAC | ALDH1A1 1992/4885MAPT 4274/4885KMT2A 3623/4885 |
| US-20140171419-A1 | ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLECULE MODULATORS HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | HGF, HDGF, MET | ALDH1A1 743/4885MAPT 4685/4885KMT2A 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.